摘要
目的:分析洛铂灌注治疗非肌层浸润性膀胱癌(NMIBC)的有效性和安全性。方法:将2021年5月至2022年4月贵州省安顺市人民医院收治的NMIBC患者100例作为本次研究的对象。将其随机分为对照组和试验组。对照组在进行经尿道膀胱肿瘤切除术(TURBT)的基础上接受吡柔比星灌注治疗,试验组在进行TURBT的基础上接受洛铂灌注治疗。对比两组的治疗效果。结果:治疗后,试验组NMIBC患者的1年生存率、2年生存率均高于对照组(P<0.05),复发率低于对照组(P<0.05)。治疗后,试验组NMIBC患者的不良反应发生率低于对照组(P<0.05)。治疗后,试验组NMIBC患者的临床有关指标(无进展生存时间、中位生存时间、各项生活质量评分)均优于对照组(P<0.05)。结论:相较于进行TURBT联合吡柔比星灌注治疗,对NMIBC患者进行TURBT联合洛铂灌注治疗的效果更为理想,具有较高的安全性和有效性。
Objective:To analyze the efficacy and safety of loplatin infusion in the treatment of non-muscular invasive bladder cancer(NMIBC).Methods:100 patients with NMIBC admitted to the People’s Hospital of Anshun,Guizhou Province from May 2021 to April 2022 were s elected as the objects of this study.They were randomly divided into control group and experimental g roup.The control group received pirubicin infusion with transurethral resection of bladder tumor(TURBT)and the experimental group received loplatin infusion with TURBT.The therapeutic effect of the two groups was compared.Results:After treatment,the 1-year survival rate and 2-year survival rate of NMIBC patients in experimental group were higher than those in control group(P<0.05),and the recurrence rate was lower than that in control group(P<0.05).After treatment,the incidence of adverse reactions in NMIBC patients in experimental group was lower than that in control group(P<0.05).After treatment,the clinical indexes(progression-free survival time,median survival time and quality of life scores)of NMIBC patients in experimental group were better than those in control group(P<0.05).Conclusions:Compared with TURBT combined with pirubicin infusion therapy,TURBT combined with loplatin infusion therapy is more effective and safe for NMIBC patients.
作者
顾九零
杨堃
李亚军
管兆龙
林峰
GU Jiuling;YANG kun;LI Yajun;GUAN Zhaolong;LIN Feng(Department of Urology,People’s Hospital of Anshun,Guizhou Province,An shun 561000,China)
关键词
非肌层浸润性膀胱癌
经尿道膀胱肿瘤切除术
洛铂灌注治疗
吡柔比星灌注治疗
安全性
有效性
non-muscular invasive bladder cancer
Transurethral resection of bladder tumors
Lobaplatin infusion therapy
Pirubicin infusion therapy
Security
validity
